CIK 0001652130 · Large accelerated filer
Intellia Therapeutics, Inc.
Sign in to watch- Ticker
- NTLA
- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 364785571
- Phone
- 857-285-6200
- Business address
- 400 TECHNOLOGY SQUARE, SUITE 100, CAMBRIDGE, MA
- 8-K Event Regulation FD disclosure · Other events
- 8-K Event Regulation FD disclosure · Other events
- SCHEDULE 13G Stake Statement of Beneficial Ownership
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- 4 Planned sale Director sold 265 shares at $8.50 ($2,253)
- ARS Other Annual Report to Security Holders
- DEFA14A Proxy Proxy Materials
- DEF 14A Proxy Proxy Statement
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- 8-K Event Bylaws or fiscal year change
- 4 Open-market sale EVP, Chief Technical Officer sold 679 shares at $8.99 ($6,104)
- 4 Grant or award President and CEO acquired 136,000 shares (grant or award)
- 4 Grant or award EVP, Chief Financial Officer acquired 47,200 shares (grant or award)
- 4 Grant or award VP, Chief Accounting Officer acquired 14,000 shares (grant or award)
- 4 Grant or award EVP, Chief Medical Officer acquired 43,200 shares (grant or award)
- 4 Grant or award EVP, Chief Scientific Officer acquired 37,600 shares (grant or award)
- 4 Open-market sale EVP, General Counsel sold 2,572 shares at $8.99 ($23,122)
- S-8 Other Securities Offered to Employees in Benefit Plans
- 10-K Report Annual Report
Page 6 of 37 · 725 filings